SEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
Lexeo Therapeutics, Inc. (Name of Issuer) |
Common Stock, par value $0.0001 per share (Title of Class of Securities) |
52886X107 (CUSIP Number) |
05/28/2025 (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
![]() |
![]() |
![]() |
SCHEDULE 13G
|
CUSIP No. | 52886X107 |
1 | Names of Reporting Persons
Affinity Healthcare Fund, LP | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
4,252,005.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
7.75 % | ||||||||
12 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13G
|
CUSIP No. | 52886X107 |
1 | Names of Reporting Persons
Affinity Asset Advisors, LLC | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
4,252,005.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
7.75 % | ||||||||
12 | Type of Reporting Person (See Instructions)
IA |
SCHEDULE 13G
|
Item 1. | ||
(a) | Name of issuer:
Lexeo Therapeutics, Inc. | |
(b) | Address of issuer's principal executive offices:
345 Park Avenue South, Floor 6, New York, NY 10010 | |
Item 2. | ||
(a) | Name of person filing:
Affinity Healthcare Fund, LP
Affinity Asset Advisors, LLC | |
(b) | Address or principal business office or, if none, residence:
450 Park Avenue
Suite 1403
New York, NY 10022 | |
(c) | Citizenship:
Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC - Delaware | |
(d) | Title of class of securities:
Common Stock, par value $0.0001 per share | |
(e) | CUSIP No.:
52886X107 | |
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
(a) | ![]() | |
(b) | ![]() | |
(c) | ![]() | |
(d) | ![]() | |
(e) | ![]() | |
(f) | ![]() | |
(g) | ![]() | |
(h) | ![]() | |
(i) | ![]() | |
(j) | ![]() please specify the type of institution: | |
(k) | ![]() | |
Item 4. | Ownership | |
(a) | Amount beneficially owned:
Affinity Asset Advisors, LLC (the "Advisor") is the investment manager of Affinity Healthcare Fund, LP (the "Fund") and exercises investment discretion with regard to the securities reported herein. As of June 4, 2025, the Fund beneficially owned an aggregate of 4,252,005 shares of Common Stock of the Issuer, including warrants to purchase 867,302 shares of Common Stock within the next sixty (60) days, or 7.75% of the outstanding shares of Common Stock of the Issuer, and the Advisor may be deemed to be the beneficial owner of such 4,252,005 shares of Common Stock of the Issuer owned by the Fund by virtue of its position as investment manager of the Fund. The Fund and the Advisor have the shared power to vote or to direct the vote and to dispose or direct the disposition of 4,252,005 shares of Common Stock of the Issuer. | |
(b) | Percent of class:
The percentage set forth in the preceding paragraph and in Row 11 of the cover page for each reporting person is based on 54,854,419 shares of Common Stock of the Issuer outstanding as of May 28, 2025 comprised of (a) the 33,196,997 shares of Common Stock of the Issuer outstanding as of May 12, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2025, (b) the 20,790,120 shares of Common Stock of the Issuer issued in connection with a private placement by the Issuer on May 28, 2025 as set forth in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 27, 2025 and (c) the 867,302 shares of Common Stock of the Issuer issuable to the Fund upon exercise of Common Warrants of the Issuer sold to the Fund in such private placement. | |
(c) | Number of shares as to which the person has:
| |
(i) Sole power to vote or to direct the vote:
Affinity Healthcare Fund, LP - 0
Affinity Asset Advisors, LLC - 0 | ||
(ii) Shared power to vote or to direct the vote:
Affinity Healthcare Fund, LP - 4,252,005
Affinity Asset Advisors, LLC - 4,252,005 | ||
(iii) Sole power to dispose or to direct the disposition of:
Affinity Healthcare Fund, LP - 0
Affinity Asset Advisors, LLC - 0 | ||
(iv) Shared power to dispose or to direct the disposition of:
Affinity Healthcare Fund, LP - 4,252,005
Affinity Asset Advisors, LLC - 4,252,005 | ||
Item 5. | Ownership of 5 Percent or Less of a Class. | |
Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
Item 9. | Notice of Dissolution of Group. | |
Not Applicable
|
Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. |
SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|